Search This Blog

Wednesday, September 21, 2022

VBI: Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine

 -VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the physician-initiated compassionate use of VBI’s 3-antigen hepatitis B vaccine in four adults chronically infected with hepatitis B virus (HBV) were presented in a poster session at the 2022 International HBV Meeting in Paris, France, on September 19.

Poster Presentation Details

  • Title: Therapeutic vaccination of chronically HBV infected patients with low-level of HBsAg using a combination of a third generation PreS/S vaccine (Sci-B-Vac™) and a nucleoside analogue
  • Session: Poster Session I
  • Date: Monday, September 19, 2022
  • Presenter: Hedwig Roggendorf, M.D., Institute of Molecular Immunology and Experimental Oncology, University Hospital Rechts der Isar, Technical University of Munich
  • Event Website:

The poster is archived on the Posters page in the News & Resources of VBI’s website, here.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.